Journal of Lipid Research, Vol 38, 2062-2070, Copyright © 1997 by Lipid Research, Inc.

ARTICLES

Phytanic acid alpha-oxidation: decarboxylation of 2-hydroxyphytanoyl- CoA to pristanic acid in human liver

NM Verhoeven, RJ Wanders, DS Schor, GA Jansen and C Jakobs
Institute for Endocrinology, Reproduction and Metabolism and Department of Clinical Chemistry, Free University Amsterdam, The Netherlands.

The degradation of the first intermediate in the alpha-oxidation of phytanic acid, 2-hydroxyphytanoyl-CoA, was investigated. Human liver homogenates were incubated with 2-hydroxyphytanoyl-CoA or 2- hydroxyphytanic acid, after which formation of 2-ketophytanic acid and pristanic acid were studied. 2-Hydroxyphytanic acid was converted into 2-ketophytanic acid and pristanic acid. When ATP, Mg2+, and coenzyme A were added to the incubation medium, higher amounts of pristanic acid were formed, whereas the formation of 2-ketophytanic acid strongly decreased. When 2-hydroxyphytanoyl-CoA was used as substrate, there was virtually no 2-ketophytanic acid formation. However, pristanic acid was formed in higher amounts than with 2-hydroxyphytanic acid as substrate. This reaction was stimulated by NAD+ and NADP+. Pristanic acid, and not pristanoyl-CoA was found to be the product of the reaction. These results suggest the existence of two pathways for decarboxylation of 2- hydroxyphytanic acid. The first one, starting from 2-hydroxyphytanic acid, involves the formation of 2-ketophytanic acid with only a small amount of pristanic acid being formed. The second pathway, which starts from 2-hydroxyphytanoyl-CoA, does not involve 2-ketophytanic acid and generates higher amounts of pristanic acid. The first pathway, which is peroxisomally localized, was found to be deficient in Zellweger syndrome, whereas the second pathway, localized in microsomes, was normally active. We conclude that the second pathway is predominant under in vivo conditions.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Arnhold, M. M. A. Elmazar, and H. Nau Prevention of Vitamin A Teratogenesis by Phytol or Phytanic Acid Results from Reduced Metabolism of Retinol to the Teratogenic Metabolite, All-trans-retinoic Acid Toxicol. Sci., April 1, 2002; 66(2): 274 - 282. [Abstract] [Full Text] [PDF]

				G. A. Jansen, E. M. Hogenhout, S. Ferdinandusse, H. R. Waterham, R. Ofman, C. Jakobs, O. H. Skjeldal, and R. J.A. Wanders Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease Hum. Mol. Genet., May 1, 2000; 9(8): 1195 - 1200. [Abstract] [Full Text] [PDF]

				J. M. Jones, J. C. Morrell, and S. J. Gould Identification and Characterization of HAOX1, HAOX2, and HAOX3, Three Human Peroxisomal 2-Hydroxy Acid Oxidases J. Biol. Chem., April 21, 2000; 275(17): 12590 - 12597. [Abstract] [Full Text] [PDF]

				G. A. Jansen, R. Ofman, S. Denis, S. Ferdinandusse, E. M. Hogenhout, C. Jakobs, and R. J. A. Wanders Phytanoyl-CoA hydroxylase from rat liver: protein purification and cDNA cloning with implications for the subcellular localization of phytanic acid {alpha}-oxidation J. Lipid Res., December 1, 1999; 40(12): 2244 - 2254. [Abstract] [Full Text] [PDF]

				T. Imanaka, K. Aihara, T. Takano, A. Yamashita, R. Sato, Y. Suzuki, S. Yokota, and T. Osumi Characterization of the 70-kDa Peroxisomal Membrane Protein, an ATP Binding Cassette Transporter J. Biol. Chem., April 23, 1999; 274(17): 11968 - 11976. [Abstract] [Full Text] [PDF]